Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective is to determine the safety, tolerability and feasibility of the inguinal intralymphatic administration of expanded allogeneic adipose-derived stem cells (eASCs)
Phase I, unicentric, single blind, clinical trial with healthy volunteers to determine the feasibility of a new administration technique.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| eASC | Experimental | eASC
|
|
| Placebo | Placebo Comparator |
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| eASC | Genetic |
|
| Measure | Description | Time Frame |
|---|---|---|
| Local and systemic reaction to administration procedure |
| 29 days |
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacodynamic parameters |
| 29 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Belén Sádaba, MD | Unidad de Investigación Clínica de la Clínica Universidad de Navarra | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Unidad de Investigación Clínica de la Clínica Universidad de Navarra | Pamplona | 31008 | Spain |
Not provided
| ID | Term |
|---|---|
| C494184 | hypothermosol |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Placebo | Drug |
|
|
|